Vol. 132, No. 30 — July 25, 1998

GOVERNMENT NOTICES

DEPARTMENT OF THE ENVIRONMENT

MIGRATORY BIRDS CONVENTION ACT, 1994

Establishment of the Inkerman Migratory Bird Sanctuary

Notice is hereby given that the Department of the Environment proposes to establish the Inkerman Migratory Bird Sanctuary, located on 15 hectares of private property two kilometres northeast of the Village of Inkerman, in New Brunswick.

The site of the proposed Inkerman Migratory Bird Sanctuary supports a nesting colony of 381 pairs of Black-crowned Night Herons and 50 pairs of Great Blue Herons. The Black-crowned Night Heron colony is the largest and most significant in the Atlantic Region, and the Great Blue Heron colony is one of the largest in New Brunswick. The birds nest on an isolated peninsula in an undisturbed wooded swamp consisting mostly of red maple and white birch.

The proposed Sanctuary will be administered under the Migratory Bird Sanctuary Regulations which are made under the authority of the Migratory Birds Convention Act. The private land owner and local community are supportive of the designation.

Further information and the area description are available from: Ms. Susan Masswohl, Canadian Wildlife Service, Department of the Environment, Ottawa, Ontario K1A 0H3, (819) 953-8582.

Interested parties are invited to submit comments in writing within 20 days from the date of publication of this notice to the Director General, Canadian Wildlife Service, Department of the Environment, Ottawa, Ontario K1A 0H3, (819) 953-6283 (Facsimile).

July 25, 1998

DAVID BRACKETT
Director General
Canadian Wildlife Service

[30-1-o]

DEPARTMENT OF HEALTH

FOOD AND DRUGS ACT

Food and Drug Regulations — Amendment

The Therapeutic Products Programme (TPP) intends to update Schedule F to the Food and Drug Regulations by adding 25 new drug substances to Part I. In addition, amendments will be made to correct the French spelling of the drug Polysulfated glycosaminoglycan and the omission of the drug cyclophosphamide from the French version of Part I of Schedule F to the Regulations (SOR/95-546).

Schedule F is a list of drug substances the sale of which is controlled under sections C.01.041 to C.01.046 of the Food and Drug Regulations. Part I of Schedule F lists substances intended for human and veterinary use which require a prescription to be sold in Canada. Part II of Schedule F lists drugs which may be sold without a prescription when the drug is intended for veterinary use and is so labelled, but does require a prescription when sold for human use. The review and introduction of new drugs onto the Canadian market necessitates periodic revisions to the schedule.

The Therapeutic Products Programme's Subcommittee on Drug Schedule Status reviews the status of chemical entities proposed for marketing. A decision regarding the necessity for prescription or other status versus nonprescription status was made for each of the drugs listed on this schedule on the basis of established and publicly available criteria. These criteria include, but are not limited to, concerns related to toxicity, pharmacologic properties and therapeutic applications.

This recommended degree of regulatory control coincides with the risk factors associated with each specific drug. The review of the information filed by the sponsor of these drugs has determined that prescription status is required at this time, as the advice of a medical practitioner is necessary in order to ensure that the consumer receives adequate risk/benefit information before taking the medication. Any alternatives to the degree of regulatory control would need to be established through additional scientific information and clinical experience.

Subject to the final approval of the Governor in Council, it is proposed that the following drug substances be added to Schedule F:

Anagrelide and its salts

Anagrelide is a platelet-reducing agent that is indicated in the management of patients with thrombocytosis at risk of thrombotic complications. The use of this drug requires close medical supervision to ensure that platelet counts do not drop to levels that place patients at risk for bleeding, with individualized instructions for the patient.

Amfebutamone and its salts

Amfebutamone is an antidepressant that is indicated for the symptomatic relief of depressive illness. The safe and effective use of amfebutamone requires that an accurate diagnosis of depression be made by the physician, who must also decide on the most appropriate form of treatment. The physician must also evaluate the contraindications, warnings and precautions associated with amfebutamone use for individual patients, must provide individualized dosage and other instructions and must maintain close medical supervision and patient follow-up throughout treatment.

Brimonidine and its salts

Brimonidine tartrate ophthalmic solution is indicated for the control of intraocular pressure in patients with chronic open-angle glaucoma and to control the post-operative intraocular pressure spikes in patients undergoing laser ocular surgery. Patients using this drug should be monitored closely by specialists in ophthalmology to ensure that the drug has produced the desired effect and that undesired side effects from the use of the drug do not occur.

Carbetocin and its salts

Carbetocin is a long-acting analogue of the pituitary hormone oxytocin that is used to stimulate contractions of the postpartum uterus to prevent uterine atony and postpartum hemorrhage. Carbetocin is to be administered intravenously as part of a major surgical procedure for the prevention of potentially serious complications of obstetrical delivery.

Cerivastatin and its salts

Cerivastatin is one of a new class of lipid-lowering compounds that reduce the production of cholesterol in the body. The drug is indicated for use with diet to reduce elevated total cholesterol and low density lipoprotein cholesterol (LDL) levels in patients with primary hypercholesterolemia. The safe and effective use of cerivastatin requires an accurate diagnosis of hypercholesterolemia be made by the physician who then must decide on the appropriate forms of treatment. The physician must also evaluate the contraindications, warnings and precautions associated with cerivastatin use in individual patients, must provide individualized dosage and other instructions, and must maintain close medical supervision and patient follow-up throughout treatment.

Emedastine and its salts

Emedastine difumarate is a benzimidazole derivative developed for the treatment of allergic conjunctivitis. This drug has a therapeutic effect based on new pharmacologic principles, currently not demonstrated by other available treatments, and therefore requires medical supervision to monitor the effectiveness of this therapy.

Fosfomycin and its salts

Fosfomycin tromethamine is an antibacterial indicated for single dose oral therapy in women with uncomplicated urinary tract infections. The initiation of therapy is dependent upon diagnosis of a urinary tract infection by a physician. The product needs to be taken under medical supervision, as the inappropriate use of antibacterials may lead to suboptimal therapy, aggravation of infection or bacterial resistance.

Irbesartan and its salts

Irbesartan is an angiotensin II AT1 receptor blocker used in the treatment of essential hypertension. Initiation of this drug therapy requires close medical supervision, as patients must receive individualized instructions on their dosage regimen. The monitoring of the effectiveness of this therapy to prevent serious adverse events known to occur with this drug is also essential.

Mibefradil and its salts

Mibefradil hydrochloride is a new type of calcium channel blocker that is used for the treatment of patients with renal or essential hypertension and for the management of chronic stable angina pectoris. The dosage of this drug must be individualized, thus requiring medical supervision to monitor the efficacy of this therapy to ensure appropriate treatment of the disease.

Montelukast and its salts

Montelukast is a new leukotriene receptor antagonist indicated for the prophylaxis and chronic treatment of asthma including prevention of day and nighttime symptoms in adult and pediatric patients 6 years of age and older. This drug should be used under a physician's care to ensure appropriate treatment of the disease. Patient monitoring is required to ensure the safe and effective use of the drug, which can include individualized instructions for the dosage regimen to be followed.

Nadroparin and its salts

Nadroparin is a low molecular weight heparin that is used for the treatment of deep vein thrombosis and pulmonary embolism. This therapy can only be used following a positive diagnosis of deep vein thrombosis or pulmonary embolism by a physician. Careful patient monitoring for the safety and effectiveness of the drug is essential.

Naratriptan and its salts

Naratriptan hydrochloride is an indole derivative that is used in the acute treatment of migraine headache attacks with or without aura. This drug should only be used where a clear diagnosis of migraine has been established by a physician. The safe and effective use of naratriptan requires that patients receive individualized instructions and assessments by a medical practitioner.

Nelfinavir and its salts

Nelfinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease that is used for the treatment of HIV infection in combination with reverse transcriptase inhibitor nucleoside analogues. The management of HIV infection with antiretroviral drugs, such as nelfinavir mesylate, necessitates physician supervision and routine laboratory monitoring, as there is a narrow margin of safety between the therapeutic and toxic doses for the combination regimen when used with concomitant AIDS therapies.

Pramipexole and its salts

Pramipexole is a new non-ergot dopamine agonist indicated for the symptomatic treatment of Parkinson's disease. The effective and safe use of pramipexole requires that an accurate diagnosis of Parkinson's disease be made by the physician, who then must decide on the most appropriate form of treatment. The physician must also evaluate the contraindications, warnings and precautions associated with pramipexole use for individual patients, must provide individualized dosage and other instructions, and must maintain close medical supervision and patient follow-up throughout treatment.

Quetiapine and its salts

Quetiapine is a new antipsychotic agent that is indicated for the acute treatment of schizophrenia. The safe and effective use of quetiapine requires that an accurate diagnosis of schizophrenia be made by the physician, who then must decide on the appropriate forms of treatment. Quetiapine has been associated with adverse events related to the central nervous system and cardiovascular system, including somnolence, dizziness and hypotension. Such adverse events require assessment and monitoring by the physician, who must determine whether dosage adjustments, changes in concomitant medications, or discontinuation of quetiapine is indicated.

Raloxifene and its salts

Raloxifene hydrochloride is a selective estrogen receptor that is indicated for the prevention of osteoporosis in postmenopausal women. The use of this drug requires close medical supervision with individualized instructions to the patient in order to ensure that the prescribed therapeutic dose is safe and effective.

Rivastigmine and its salts

Rivastigmine tartrate is an anticholinesterase indicated for the symptomatic treatment of patients with mild to moderate Alzheimer's disease. This drug needs to be prescribed by clinicians familiar with Alzheimer's disease to ensure proper diagnosis of patients. Close medical supervision with individualized instructions to the patient is required in order to ensure that the prescribed therapeutic dose is safe and effective.

Tamsulosin and its salts

Tamsulosin is the first of a new class of drugs indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. The safe and effective use of tamsulosin requires individualized patient instructions by a physician and monitoring of adverse events that may occur with this therapy.

Tizanidine and its salts

Tizanidine is an imidazoline derivative, which acts as an agonist at alpha₂ adrenergic receptor sites. This drug is used for the management of increased muscle tone associated with spasticity. The safe and effective use of tizanidine requires that patients receive individualized instructions and assessments by a medical practitioner.

Tolcapone

Tolcapone is used for the treatment of Parkinson's disease. The safe and effective use of tolcapone will require prior diagnosis of Parkinson's disease. Medical judgment as to when it might be desirable to add tolcapone to the treatment regimen of parkinsonian patients, and careful follow-up to ascertain effectiveness and safety, is also required.

Tolterodine and its salts

Tolterodine is a competitive muscarinic receptor antagonist used in the management of symptoms of overactive bladders, characterized by urgency, frequency and urge incontinence. The safe and effective use of tolterodine requires that patients receive individualized instructions and assessments by a medical practitioner.

Toremifene and its salts

Toremifene is used for the treatment of hormone-dependent metastatic breast cancer in postmenopausal women. The safe and effective use of toremifene requires that patients receive individualized instructions and assessments by a medical practitioner.

Valsartan and its salts and derivatives

Valsartan is an angiotensin II AT1 receptor blocker used in the treatment of mild to moderate essential hypertension. Initiation of this drug therapy requires close medical supervision, as patients must receive individualized instructions on their dosage regimen. The monitoring of the effectiveness of this therapy to prevent serious adverse events known to occur with this drug is also essential.

Zafirlukast and its salts

Zafirlukast is a leukotriene receptor antagonist used for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. This drug should be used under a physician's care to ensure appropriate treatment of the disease. Patient monitoring is required to ensure the safe and effective use of the drug, which can include individualized instructions for the dosage regimen to be followed.

Zolmitriptan and its salts

Zolmitriptan is an indole derivative that is used for the acute treatment of migraine headache attacks with or without aura. The safe and effective use of zolmitriptan requires that patients receive individualized instructions and assessments by a medical practitioner.

Consultation has been initiated with affected stakeholders including the pharmaceutical industry associations, Registrars of Medicine and Pharmacy, and provincial Deputy Ministers of Health. There is a comment period of 60 days from the date of publication of this notice. This initiative is also posted on the Health Canada, Therapeutic Products Programme, Web site under "Drugs, Schedule Amendments, Early Consultation" (http://www. hc-sc.gc.ca/hpb-dgps/therapeut/drhtmeng/schedule.html#early).

Comments on this notice may be sent to Nancy Shadeed, Policy Division, Bureau of Policy and Coordination, Therapeutic Products Programme, Health Protection Building, Address Locator 0702B1, Tunney's Pasture, Ottawa, Ontario K1A 0L2, or by the Internet to nancy_shadeed@hc-sc.gc.ca within 60 days. All comments should cite the Canada Gazette, Part I, and the date of the publication of this notice.

July 17, 1998

DANN M. MICHOLS
Director General
Therapeutic Products Programme

[30-1-o]

DEPARTMENT OF INDUSTRY

RADIOCOMMUNICATION ACT

Notice No. DGRB-005-98 — Extension to Comment Period for Notice No. DGRB-001-98 — Spectrum Licence Fees for Mobile Satellite Services Using Radio Spectrum Above 1 GHz

The availability of the document Consultation on Spectrum Licence Fees for Mobile Satellite Services in Canada Using Mobile Satellite Service Spectrum above 1 GHz was announced in the Canada Gazette Notice No. DGRB-001-98 on Saturday, June 13, 1998. Given that this notice provided for a 60 day comment period, the deadline for receipt of comments was August 12, 1998.

The purpose of this notice is to advise all interested parties that the deadline for receipt of comments has been extended to Friday, September 11, 1998.

Comments should be submitted as indicated in Notice No. DGRB-001-98 no later than Friday, September 11, 1998.

Copies of the documents are available on the Internet address at:

World Wide Web (WWW) http://strategis.ic.gc.ca/spectrum

July 25, 1998

JAN SKORA
Director General
Radiocommunication and
Broadcasting Regulatory Branch

[30-1-o]

DEPARTMENT OF INDUSTRY

RADIOCOMMUNICATION ACT

Notice No. SMSE-007-98 — Interference-Causing Equipment Standard (ICES)

Notice is hereby given that Industry Canada is releasing the following document for public comment:

ICES-005 Interference-Causing Equipment Standard for Radio Frequency Lighting Devices (RFLD) ICES-005, Issue 1 — Draft.

This draft standard is a new initiative by Industry Canada. The purpose of ICES-005 is to impose limits on radio noise emissions from radio frequency lighting devices, or RFLD. The requirements set out in ICES-005 are harmonized with those for RFLD set out in the FCC Rules Part 18. As an Interference-Causing Equipment Standard, ICES-005 will be given effect by the Radiocommunication Regulations, under which it is to be designated as a Category II Equipment Standard.

In accordance with section 20 of the Radiocommunication Regulations, the Category II Equipment Standards List is published in the Canada Gazette, Part I, and provides a list of all technical standards applicable to interference-causing equipment. The effective date of the above standard will be the publication date of the amended list which will include this standard. Compliance with a listed standard is required in accordance with the Radiocommunication Regulations.

The ICES-005, Issue 1 — Draft document is available at the following Internet WWW addresses:

http://strategis.ic.gc.ca/spectrum for the English version

and

http://strategis.ic.gc.ca/spectre for the French version.

Interested parties may submit comments concerning this draft standard to the Director General, Spectrum Engineering Branch, Industry Canada, 300 Slater Street, Ottawa, Ontario K1A 0C8 within 60 days from the date of publication of this notice. All representations must cite the Canada Gazette, Part I notice publication date, title and the notice reference number.

July 17, 1998

R. W. MCCAUGHERN
Director General
Spectrum Engineering Branch

[30-1-o]

DEPARTMENT OF NATIONAL REVENUE

The following notice of proposed revocation was sent to the charities listed below:

"Notice is hereby given, pursuant to paragraph 168(1)(a) of the Income Tax Act, that I propose to revoke the registration of the charities listed below and that by virtue of paragraph 168(2)(a) thereof, the revocation of the registration is effective on the date of publication of this notice in the Canada Gazette."

Registration Number*	Business Number	Name Address
0003145-38	107909939RR0048	ST. ANDREW'S PARISH, VULCAN, ALTA.
0027920-30	119179802RR0002	ST. JOHN'S CHURCH, BROMONT, QUE.
0032979-32	889706040RR0001	ZION LUTHERAN CHURCH, WINNIPEG, MAN.
0142786-75	118802909RR0001	BELLEVILLE UTILITIES COMMISSION EMPLOYEES' CHARITY TRUST, BELLEVILLE, ONT.
0279067-47	119098879RR0001	PRESBYTERIAN WOMEN'S MISSIONARY SOCIETY, WESTERN DIVISION, CAINTOWN EVENING AUXILIARY, ST. PAUL'S PRESBYTERIAN CHURCH, MALLORYTOWN, ONT.
0303347-75	889604062RR0001	WORKERS' COMPENSATION BOARD CHARITIES TRUST FUND, EDMONTON, ALTA.
0304444-09	132410671RR0237	SOCIÉTÉ ST-VINCENT-DE-PAUL CONFÉRENCE ST-COEUR DE MARIE DE QUÉBEC, QUÉBEC (QUÉ.)
0348607-59	119310084RR0001	137TH BATTALION, C.E.F. MEMORIAL FUND, CALGARY, ALTA.
0350652-01	119228245RR0001	THE CONCORD HOMES SOCIETY, WHITE ROCK, B.C.
0389692-39	118948108RR0001	GRIERSVILLE CHURCH OF CHRIST, MEAFORD, ONT.
0395632-37	887052397RR0001	PRESBYTERIAN REFORMED CHURCH, WILLOWDALE, ONT.
0405803-51	889004248RR0001	NATIONAL DEFENCE MEDICAL CENTRE NDMC UNIT FUND, OTTAWA, ONT.
0424994-44	119039873RR0001	MICKSBURG UNITED CHURCH, COBDEN, ONT.
0445254-75	889330668RR0001	SEARS CANADA INC. EMPLOYEES CHARITABLE FUND, HALIFAX, N.S.
0492686-59	118785898RR0001	AMNESTY INTERNATIONAL CANADA KITCHENER-WATERLOO GROUP 9, WATERLOO, ONT.
0518274-46	131035461RR0001	LES RELIGIEUSES ADORATRICES DU PRÉCIEUX SANG DE WATERVILLE, GRANDE CACHE (ALB.)
0521534-59	119760528RR0001	FAPEL, FÉDÉRATION DES ASSOCIATIONS POUR LA PROTECTION DE L'ENVIRONNEMENT DES LACS, MONTRÉAL (QUÉ.)
0631143-39	107396905RR0026	SONRISE FOURSQUARE CHURCH, CAMBRIDGE, ONT.
0659417-09	890142144RR0001	LES GRANDS FRÈRES ET GRANDES SOEURS DU SAGUENAY, CHICOUTIMI (QUÉ.)
0676700-21	119192573RR0001	STONEWALL COLLEGIATE STUDENT EDUCATIONAL ASSISTANCE FUND, STONEWALL, MAN.
0704445-39	107705048RR0001	MINNEDOSA CHRISTIAN ASSEMBLY, MINNEDOSA, MAN.
0711366-39	886609999RR0001	EAGLE RIDGE COMMUNITY CHURCH, KAMLOOPS, B.C.
0725101-03	894556182RR0001	PAOLUCCI CHARITABLE FOUNDATION MARIO & ANTONIA, RICHMOND HILL, ONT.
0746057-39	131589103RR0001	LIVING HOPE CHRISTIAN REFORMED CHURCH, WOODBRIDGE, ONT.
0749143-50	108090747RR0001	OLD STRATHCONA MODEL AND TOY MUSEUM ASSOCIATION, EDMONTON, ALTA.
0754127-15	118958990RR0001	HOGARTH-WESTMOUNT HOSPITAL AUXILIARY, THUNDER BAY, ONT.
0760413-56	118841683RR0001	CECILE MARTIN MEMORIAL PARK DEVELOPMENT ASSOCIATION, BARRHEAD, ALTA.
0766139-36	886167394RR0001	CARREFOUR DU PLEIN ÉVANGILE, LAVAL (QUÉ.)
0767889-57	119145795RR0001	SERENITY RETREAT ASSOCIATION, CALGARY, ALTA.
0782474-50	119208742RR0001	TATAMAGOUCHE HISTORICAL AND CULTURAL SOCIETY, TATAMAGOUCHE, N.S.
0785386-36	107833295RR0231	HOLMAN PENTECOSTAL TABERNACLE, KUGLUKTUK, N.W.T.
0847194-59	128285095RR0001	WEST PARRY SOUND S.O.S. INFORMATION CENTRE, PARRY SOUND, ONT.
0850750-09	886596287RR0001	ST. ANNE'S CASA HOGAR CHILDREN'S FOUNDATION, GRANDE CACHE, ALTA.
0871087-09	132388786RR0001	ATIKOKAN INJURED WORKERS SUPPORT GROUP, ATIKOKAN, ONT.
0901173-21	887938843RR0001	CHAMPLAIN CHAPTER R.N.A.O CHARITABLE TRUST, PETAWAWA, ONT.
0911826-59	891225146RR0001	PRIDE STOUGHTON, STOUGHTON, SASK.
0929141-39	892552969RR0001	CHURCH OF GOD (SEVENTH DAY) HISPANIC, MISSION, B.C.
0936401-39	890821994RR0001	INDONESIAN CATHOLIC SOCIETY (UKIBC), BURNABY, B.C.
0914929-56	139921209RR0001	ISLANDS SUPER SENIOR CITIZENS ADVISORY COMMITTEE, WESPORT, DIGBY COUNTY, N.S.
0987016-09	138274295RR0001	CENTRE D'AIDE AUX ORGANISMES COMMUNAUTAIRES ET BÉNÉVOLES DE LÉVIS, LÉVIS (QUÉ.)
0997460-09	891338949RR0001	JUMP STREET YOUTH RESIDENCE OF OTTAWA-CARLETON, OTTAWA, ONT.
1014521-56	141298497RR0001	SPORTS ET LOISIRS PASSE-PARTOUT INC., MONTRÉAL (QUÉ.)
1019439-09	889098075RR0001	KIRKLAND LAKE FOOD BANK, KIRKLAND LAKE, ONT.
1028505-54	891861445RR0001	A.N.S. ANIMALS IN NEED SOCIETY, RICHMOND, B.C.
1040054-21	890280977RR0001	CANADIAN FEDERATION OF UNIVERSITY WOMEN PICTON AND DISTRICT SCHOLARSHIP/BURSARY FUND, PICTON, ONT.
1043637-21	895766467RR0001	HUGHENDEN/PROVOST SCHOOL FOUNDATION SOCIETY, CZAR, ALTA.
1050988-56	888956174RR0001	CAPITAL SKATING PARK INC., CARP, ONT.
1058171-39	894996560RR0001	VALLEY FULL GOSPEL ASSEMBLY COURTENAY, BC, NELSON, B.C.
1106459-59	888105541RR0001	CENTRAL KOOTENAY CRIME STOPPERS SOCIETY, CRESTON, B.C.
1121183-59	883748980RR0001	BUNCLODY WILLING WORKERS, CARROLL, MAN.

* The charities are listed from the lowest registration number to the highest.

NEIL BARCLAY
Director
Charities Division

[30-1-o]

DEPARTMENT OF NATURAL RESOURCES

CANADA-NOVA SCOTIA OFFSHORE PETROLEUM BOARD

Call for Bids No. NS98-1

The Canada-Nova Scotia Offshore Petroleum Board (the "Board") has made a call for bids pursuant to the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act, S.C., 1988, c. 28, as amended, and the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation (Nova Scotia) Act, S.N.S., 1987, c. 3, as amended, for three Exploration Licences covering the following parcels of land north and east of Sable Island Offshore Nova Scotia (the "Lands"):

Land Parcel No. 1

Grid	Hectares	Sections
44-40-57-00	9 195	51-55, 61-65, 71-75, 81-85, 91-95
44-40-57-15	36 740	1-100
44-30-57-15	18 400	6-10, 16-20, 26-30, 36-40, 46-50, 56-60, 66-70, 76-80, 86-90, 96-100
44-40-57-30	9 195	1-5, 11-15, 21-25, 31-35, 41-45
44-30-57-30	29 470	3-10, 13-20, 23-30, 33-40, 43-50, 53-60, 63-70, 73-80, 83-90, 93-100
Total hectares	103 000
Land Parcel No. 2
Grid	Hectares	Sections
44-40-57-45	11 040	1-3, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93
44-30-57-45	36 850	1-100
44-20-57-45	7 380	9, 10, 19, 20, 29, 30, 39, 40, 49, 50, 59, 60, 69, 70, 79, 80, 89, 90, 99, 100
44-30-58-00	27 650	1-10, 11-20, 21-30, 31-40, 41-50, 51-55, 61-65, 71-75, 81-85, 91-95
44-20-58-00	18 450	6-10, 16-20, 26-30, 36-40, 46-50, 56-60, 66-70, 76-80, 86-90, 96-100
44-30-58-15	11 070	1-13, 11-13, 21-23, 31-33, 41-43, 51-53, 61-63, 71-73, 81-83, 91-93
44-20-58-15	22 150	5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, 75-80, 85-90, 95-100
Total hectares	134 590
Land Parcel No. 3
Grid	Hectares	Sections
44-30-59-30	33 906	1-68, 71-78, 81-88, 91-98
44-30-59-45	23 592	1-8, 11-18, 21-28, 31-38, 41-48, 51-58, 61-68, 71-78
44-20-59-30	18 450	6-10, 16-20, 26-30, 36-40, 46-50, 56-60, 66-70, 76-80, 86-90, 96-100
44-20-59-45	14 760	6-10, 16-20, 26-30, 36-40, 46-50, 56-60, 66-70, 76-80
Total hectares	90 708

Bid selection

Bidding on each parcel will be based solely on the amount of money proposed to be spent on exploration during Period 1 of the term of the Exploration Licence, determined in accordance with the schedule of Allowable Expenditures set out below. No other factors will be considered in selecting the winning bid, but the Board is not obligated to accept any bid. The minimum bid per parcel that will be considered is $1,000,000 (Canadian) of work expenditure.

Allowable Expenditures

Seismic (2D): $1,500/kilometre (includes mobilization and demobilization, field acquisition, processing, interpretation and preparation of report).

Seismic (3D): $100,000 plus $30,000/square kilometre (includes mobilization and demobilization, field acquisition, processing, interpretation and preparation of report).

Drilling: $2,500,000 for each well plus $250,000/day while on location (includes mobilization and demobilization, environmental and geological studies, regional office and supervision, support vessels, helicopters, etc.)

Wellsite Surveys: $275,000 flat allowance per site.

Overheads: included in above rates.

Terms and conditions of Exploration Licence

Environmental Studies

In accordance with the legislation, prior to the authorization of any petroleum related activities on "the Lands" the operator must demonstrate to the satisfaction of the Board that such activities can be conducted in an environmentally safe manner.

Term

The term of each Exploration Licence will be nine years, consisting of two consecutive periods referred to as Period 1 and Period 2.

Period 1 is five years long, but will be extended by one year if a well is commenced or a Drilling Deposit in the amount of $250,000 is posted before the end of the fifth year. If a Drilling Deposit is posted it will be refunded in full if the licence is validated for Period 2 by the drilling of a well. If a validation well is not drilled, the Drilling Deposit will be forfeited upon the termination of the licence. Allowable Expenditures cannot be applied against the Drilling Deposit.

Period 2 immediately follows Period 1 and consists of the balance of the nine-year term of the licence. In order to validate the licence for Period 2, the drilling of a well must be commenced within Period 1 and diligently pursued to termination in accordance with good oilfield practice. Failure to fulfill this drilling requirement will result in the termination of the licence at the end of Period 1. The validation well must adequately test a valid geological target to be declared to the Board by the interest owner prior to the commencement of the well.

Work Deposit

The successful bidder will be required to post security for the performance of work in the amount of 25 percent of its work expenditure bid (the "Work Deposit"). The successful bidder must post this Work Deposit within 15 days of being notified that its bid was successful, as a condition of issuance of the Exploration Licence. Work Deposits must be in the form of cash or bonds, or promissory notes, payable on demand to the Receiver General for Canada, that a Canadian chartered bank has agreed to honour on presentment for payment. The form of security documents must be acceptable to the Board.

Upon the completion of work from time to time the interest owner may apply to the Board for approval of Allowable Expenditures incurred. The Work Deposit will be refunded to the extent of 25 percent of approved Allowable Expenditures. No interest is paid on the Work Deposit.

The interest owner is not obligated to perform work under the licence. However if the interest owner does not perform work in the full amount of its work expenditure bid, the unrefunded balance of the Work Deposit will be forfeited upon the termination of this licence.

Rentals

No rentals are payable in respect of Period 1. Refundable rentals are payable during Period 2 at the rate of $2.50 a hectare for each year of Period 2. Rentals are payable annually, in advance. Rentals will be refunded upon application to the Board to the extent of approved Allowable Expenditures incurred during Period 2. Allowable Expenditures incurred in a particular year of Period 2 that are in excess of what is required to reduce rentals to zero in that year may be carried backward or forward for the purpose of reducing rentals paid or payable in previous or subsequent years of Period 2. Allowable Expenditures incurred in Period 1 after completion of the first well may also be carried forward for this purpose into Period 2 to the extent that they have not been taken into account in refunding all or part of the Work Deposit.

Indemnity

Interest Holders are required to indemnify the Board and Her Majesty the Queen in right of Canada and in right of the province of Nova Scotia against all claims that may be made by any person by reason of anything done or omitted to be done under the licence by, through or under the interest owner or an interest holder, in relation to those portions of the Lands with respect to which they hold shares.

Submission of bids

Bids must be received by the Board before 4:00 p.m. on November 3, 1998, at the following address: Canada-Nova Scotia Offshore Petroleum Board, T.D. Centre, 6th Floor, 1791 Barrington Street, Halifax, Nova Scotia B3J 3K9.

Bids must be in the form attached as Appendix II to the call for bids and must be submitted in a sealed envelope marked "CALL FOR BIDS NS98-1." The bid form is available from the Board (see below). Bids not meeting the requirements of the call will not be considered.

Each bid must be accompanied by a Bid Deposit in the amount of $10,000, in the form of a certified cheque or bank draft payable to the Receiver General for Canada. Bid Deposits will be returned to unsuccessful bidders, without interest, following announcement of the winning bid. The Bid Deposit of the successful bidder will be returned, without interest, when the Work Deposit is posted and any outstanding Environmental Studies Research Fund (ESRF) levies are paid.

The failure of the successful bidder to post the Work Deposit within the specified time will result in forfeiture of the Bid Deposit and disqualification of the bid, and in that event the Board may, if it sees fit, award the Exploration Licence to the second highest bidder without making another call for bids.

Further Information

This notice contains a summary only of the terms and conditions of the call for bids. Interested persons should obtain a copy of the full text of the call for bids, which will prevail over this summary in the case of any conflict or inconsistency. A complete bid package, including the bid form and the form of Exploration Licence, may be obtained free of charge from the Board at the above address, or may be requested by fax sent to (902) 422-1799 or by telephone at (902) 422-5588.

Halifax, May 4, 1998

CANADA-NOVA SCOTIA OFFSHORE
PETROLEUM BOARD
J. E. (JIM) DICKEY
Chief Executive Officer

[30-1-o]

DEPARTMENT OF NATURAL RESOURCES

CANADA-NOVA SCOTIA OFFSHORE PETROLEUM BOARD

Issuance of Exploration Licences

As required by subsection 62(4) of the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act, S.C., 1988, c. 28, and subsection 65(4) of the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation (Nova Scotia) Act, S.N.S., 1987, c. 3, notice is hereby given that the Canada-Nova Scotia Offshore Petroleum Board has issued Exploration Licence No. 2359 to Chevron Canada Resources Limited, Exploration Licence No. 2360 and Exploration Licence No. 2363 to PanCanadian Petroleum Limited, Exploration Licence No. 2361 to Mobil Oil Canada Properties (40 percent), Shell Canada Limited (40 percent) and Imperial Oil Resources Limited (20 percent), Exploration Licence No. 2362 to MariCo Oil & Gas Corporation, Exploration Licence No. 2364 and Exploration Licence No. 2365 to Hunt Oil Company. The effective date of these licences is July 1, 1998. A summary of the terms and conditions of these licences was previously published in the Canada Gazette and in the Royal Gazette (Nova Scotia), as part of the notices of Call For Bids No. NS97-2 and Call For Bids No. NS97-3. The full text of both calls for bids and copies of the exploration licences are available from the Board on request.

CANADA-NOVA SCOTIA OFFSHORE
PETROLEUM BOARD
J. E. (JIM) DICKEY
Chief Executive Officer

[30-1-o]

NOTICE:
The format of the electronic version of this issue of the Canada Gazette was modified in order to be compatible with extensible hypertext markup language (XHTML 1.0 Strict).